These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 10811463)

  • 1. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
    Lin CP; Huang MJ; Chang IY; Lin WY
    Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
    Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
    Zhang X; Yang L; Qiao Z
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
    Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
    Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T; Westervelt P; Hess JL
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survey of outcome in acute promyelocytic leukemia.
    Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
    Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
    Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
    Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    Tomita A; Kiyoi H; Naoe T
    Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.